The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions.
Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA 98109, USA.
Evan Y
EY
Yu
Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
William K
WK
Oh
D000726:Androgen Antagonists / Q000008:administration & dosage; D059002:Androgen Receptor Antagonists / Q000008:administration & dosage; D000736:Androstenes; D000737:Androstenols / Q000008:administration & dosage; D001549:Benzamides; D001859:Bone Neoplasms / Q000556:secondary / Q000628:therapy; D006801:Humans; D008297:Male; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000008:administration & dosage / Q000031:analogs & derivatives; D064129:Prostatic Neoplasms, Castration-Resistant / Q000628:therapy*; D011868:Radioisotopes / Q000008:administration & dosage; D019275:Radiopharmaceuticals / Q000008:administration & dosage; D011883:Radium / Q000008:administration & dosage; D015398:Signal Transduction / Q000187:drug effects; D014020:Tissue Extracts / Q000008:administration & dosage
D000726:Androgen Antagonists; D059002:Androgen Receptor Antagonists; D000736:Androstenes; D000737:Androstenols; D001549:Benzamides; D009570:Nitriles; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D014020:Tissue Extracts; D010669:Phenylthiohydantoin; C511774:sipuleucel-T; C540278:enzalutamide; C089740:abiraterone; C581106:radium Ra 223 dichloride; D011883:Radium